EA200700564A1 - 2`-фторнуклеозиды - Google Patents

2`-фторнуклеозиды

Info

Publication number
EA200700564A1
EA200700564A1 EA200700564A EA200700564A EA200700564A1 EA 200700564 A1 EA200700564 A1 EA 200700564A1 EA 200700564 A EA200700564 A EA 200700564A EA 200700564 A EA200700564 A EA 200700564A EA 200700564 A1 EA200700564 A1 EA 200700564A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phosphate
pharmaceutically acceptable
base
alkyl
purine
Prior art date
Application number
EA200700564A
Other languages
English (en)
Russian (ru)
Inventor
Рэймонд Ф. Шинази
Деннис К. Лиотта
Чунг К. Чу
Дж. Джеффри Макати
Дзунксинг Ши
Йонгсеок Чой
Кийеонг Ли
Дзоон Х. Хонг
Original Assignee
Эмори Юниверсити
Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмори Юниверсити, Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк. filed Critical Эмори Юниверсити
Publication of EA200700564A1 publication Critical patent/EA200700564A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Silicon Polymers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA200700564A 1998-02-25 1999-02-25 2`-фторнуклеозиды EA200700564A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7589398P 1998-02-25 1998-02-25
US8056998P 1998-04-03 1998-04-03

Publications (1)

Publication Number Publication Date
EA200700564A1 true EA200700564A1 (ru) 2007-08-31

Family

ID=26757404

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200700564A EA200700564A1 (ru) 1998-02-25 1999-02-25 2`-фторнуклеозиды
EA200000870A EA008609B1 (ru) 1998-02-25 1999-02-25 2'-фторнуклеозиды

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200000870A EA008609B1 (ru) 1998-02-25 1999-02-25 2'-фторнуклеозиды

Country Status (17)

Country Link
US (7) US6348587B1 (https=)
EP (3) EP2392580A1 (https=)
JP (2) JP2002504558A (https=)
KR (3) KR100954390B1 (https=)
CN (1) CN100349913C (https=)
AT (1) ATE344271T1 (https=)
AU (2) AU2787199A (https=)
BR (1) BR9908270A (https=)
CA (1) CA2322008C (https=)
DE (1) DE69933860T2 (https=)
DK (1) DK1058686T3 (https=)
EA (2) EA200700564A1 (https=)
ES (1) ES2276515T3 (https=)
IL (3) IL138037A0 (https=)
MX (1) MXPA00008348A (https=)
PT (1) PT1058686E (https=)
WO (1) WO1999043691A1 (https=)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
WO1999043691A1 (en) 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
KR20030005197A (ko) 2000-02-18 2003-01-17 샤이어 바이오켐 인코포레이티드 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법
EP1964569A3 (en) 2000-04-13 2009-07-22 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) * 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
FR2810319A1 (fr) * 2000-06-15 2001-12-21 Ppg Sipsy Composes alpha-phenylsulfinyl-alpha-halogeno-butyrolactone et halogeno-2-buten-2-olide-4 utiles pour la preparation de composes halogeno-2-oxymethyl-4-furanone (4h)
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
WO2002032920A2 (en) * 2000-10-18 2002-04-25 Pharmasset Limited Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
SK286630B6 (sk) * 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US6900315B2 (en) 2001-02-06 2005-05-31 Yale University 2-amino-9H-purin-9-yl compounds and methods for inhibiting/treating HIV infections and AIDS related symptoms
CA2439836A1 (en) 2001-03-01 2002-09-12 Pharmasset, Inc. Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
WO2002069903A2 (en) * 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1478322A4 (en) 2001-06-22 2007-08-08 Pharmasset Ltd Beta 2'-OR 3'-HALONUCLEOSIDE
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
US7049303B2 (en) * 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
AU2002365234B2 (en) * 2001-12-14 2009-01-29 Pharmasset Inc N4-acylcytosine nucleosides for treatment of viral infections
JP2005522443A (ja) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
WO2004013300A2 (en) 2002-08-01 2004-02-12 Pharmasset Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
US6884880B2 (en) * 2002-08-21 2005-04-26 Ash Stevens, Inc. Process for the preparation of 9-β-anomeric nucleoside analogs
US7902203B2 (en) * 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en) * 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
NZ540913A (en) * 2002-12-23 2008-02-29 Idenix Cayman Ltd Process for the production of 3'-nucleoside prodrugs
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
KR20060015542A (ko) * 2003-04-28 2006-02-17 이데닉스 (케이만) 리미티드 산업 규모의 뉴클레오시드 합성
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
WO2005003374A2 (en) * 2003-06-30 2005-01-13 Idenix (Cayman) Limited SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
NZ546055A (en) 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
WO2005026186A1 (de) * 2003-09-12 2005-03-24 Max-Delbrück-Centrum für Molekulare Medizin Β-l-nucleoside und ihre verwendung als pharmazeutische mittel zur behandlung viraler erkrankungen
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
US7405220B2 (en) * 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
KR100839394B1 (ko) * 2004-06-09 2008-06-20 에프. 호프만-라 로슈 아게 피라졸로 피리미딘
CA2568379A1 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
CA2571675A1 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CA2571079A1 (en) 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
WO2006021341A1 (en) * 2004-08-23 2006-03-02 F. Hoffmann-La Roche Ag Antiviral 4’-azido-nucleosides
US8492539B2 (en) * 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
WO2006093801A1 (en) * 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
CA2600886A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
BRPI0614205A2 (pt) 2005-08-01 2016-11-22 Merck & Co Inc composto, composição farmacêutica, e, uso de composto
US7705009B2 (en) * 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
CA2632626C (en) * 2005-12-09 2011-10-11 F. Hoffmann-La Roche Ag Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
EP1979349B1 (en) * 2005-12-21 2010-07-28 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
US7910595B2 (en) * 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
ES2422290T3 (es) * 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
KR101237312B1 (ko) * 2006-02-10 2013-03-04 삼진제약주식회사 피리미딘다이온 유도체를 포함하는 ｃ형 간염의 예방 및치료용 약학 조성물
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
US9644039B2 (en) 2006-03-24 2017-05-09 The Regents Of The University Of California Acid-degradable and bioerodible modified polyhydroxylated materials
WO2010005847A1 (en) * 2008-07-08 2010-01-14 The Regents Of The University Of California Acid-degradable and bioerodible modified polyhydroxylated materials
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
WO2008011337A1 (en) * 2006-07-19 2008-01-24 Abbott Laboratories Hcv inhibitors
US20090298708A1 (en) * 2006-08-23 2009-12-03 Masad Damha J 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside 5'-triphosphates and their use in enzymatic nucleic acid synthesis
KR101057239B1 (ko) 2006-10-10 2011-08-16 에프. 호프만-라 로슈 아게 뉴클레오사이드 리보푸라노실 피리미딘의 제조
AP2009004812A0 (en) * 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor
CN101583372A (zh) 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
JP2010507656A (ja) 2006-10-24 2010-03-11 メルク エンド カムパニー インコーポレーテッド Ｈｃｖｎｓ３プロテアーゼ阻害剤
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2008057209A1 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
AU2007318164B2 (en) 2006-10-27 2013-02-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
US8236950B2 (en) * 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
CN103224506A (zh) 2006-12-20 2013-07-31 P.安杰莱蒂分子生物学研究所 抗病毒的吲哚
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
JP2010515680A (ja) 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
JP2010520200A (ja) 2007-02-28 2010-06-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド 特定のマトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤を使用する肝疾患を治療する方法
KR101582570B1 (ko) * 2007-03-23 2016-01-06 써던 리서취 인스티튜트 관절염 치료 및 예방 방법
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
AU2008277440A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
WO2009058800A2 (en) * 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthesis of nucleosides
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
AU2009241445A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US20090274686A1 (en) * 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201004632A (en) 2008-07-02 2010-02-01 Idenix Pharmaceuticals Inc Compounds and pharmaceutical compositions for the treatment of viral infections
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
PT2540350E (pt) 2008-07-22 2014-08-27 Merck Sharp & Dohme Combinações de um composto de quinoxalina macrocílico o qual é um inibidor da protease ns3 do hcv com outros agentes do hcv
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
BRPI1010809A2 (pt) * 2009-05-12 2015-10-13 Southern Res Inst composto, composição farmacêutica, métodos de tratar câncer em mamífero e usos de compostos e de composição farmacêutica
EP2429568B1 (en) 2009-05-13 2016-08-17 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
TWI583692B (zh) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CA2780044A1 (en) 2009-11-14 2011-05-19 F. Hoffmann-La Roche Ag Biomarkers for predicting rapid response to hcv treatment
US8816074B2 (en) * 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011067195A1 (en) 2009-12-02 2011-06-09 F. Hoffmann-La Roche Ag Biomarkers for predicting sustained response to hcv treatment
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
US9284188B2 (en) 2010-09-03 2016-03-15 The Regents Of The University Of California Cytosolic delivery of materials with endosome-disrupting colloids
JP5857053B2 (ja) 2010-09-21 2016-02-10 エナンタ ファーマシューティカルズ インコーポレイテッド 大環式プロリン由来ｈｃｖセリンプロテアーゼ阻害剤
JP5909495B2 (ja) 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012142093A2 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013009735A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9408863B2 (en) 2011-07-13 2016-08-09 Merck Sharp & Dohme Corp. 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
EP2776438A4 (en) * 2011-11-10 2015-04-29 Inhibitex Inc SUBSTITUTED PURIN NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013106344A1 (en) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
US8673926B2 (en) 2012-02-14 2014-03-18 University Of Georgia Research Foundation, Inc. Spiro[2.4]heptanes for treatment of flaviviridae infections
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
EP2900684A2 (en) 2012-09-29 2015-08-05 Novartis AG Cyclic peptides and use as medicines
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
EP2938624A1 (en) 2012-11-14 2015-11-04 IDENIX Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
RU2534613C2 (ru) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
CN105722977A (zh) 2013-10-30 2016-06-29 绿色生活生物技术有限责任公司 用于柑橘绿化枯萎病的发病定量系统和治疗方法
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US10683321B2 (en) 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
JP6743135B2 (ja) 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US11234454B2 (en) 2016-12-15 2022-02-01 Société des Produits Nestlé S.A. Compositions and methods that modulate cholesterol in a companion animal
US11758928B2 (en) 2016-12-15 2023-09-19 Société des Produits Nestlé S.A. Compositions and methods that modulate phosphorus or enzymes in a companion animal
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
JP7496132B2 (ja) * 2018-08-31 2024-06-06 国立大学法人 鹿児島大学 核酸アナログ及び抗ｂ型肝炎ウイルス剤
KR102835299B1 (ko) 2018-12-04 2025-07-18 브리스톨-마이어스 스큅 컴퍼니 다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US20240261317A1 (en) * 2021-05-17 2024-08-08 Rome Therapeutics, Inc. Methods of treating medical conditions and inhibiting line1 reverse transcriptaseusing a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic acid or related compound
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US438395A (en) 1890-10-14 Vania
US3870700A (en) 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
JPS525517B2 (https=) 1973-09-05 1977-02-14
JPS5123512B2 (https=) 1973-09-05 1976-07-17
JPS525518B2 (https=) 1973-10-15 1977-02-14
US4000137A (en) 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5384981A (en) 1976-09-03 1978-07-26 Taiho Pharmaceutical Co Ltd Method of producing 11*tetrahydroo22furanyl**55 fluorouracile
US4211773A (en) 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
JPS5668674A (en) 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4625020A (en) 1983-11-18 1986-11-25 Bristol-Myers Company Nucleoside process
US4666892A (en) 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds
JPS61146482A (ja) 1984-12-20 1986-07-04 工業技術院長 異構造異自由度バイラテラル・マスタスレイブ・マニピユレ−タの制御装置
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5446029A (en) 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
SE8701605D0 (sv) 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
DE3715666A1 (de) 1987-05-11 1988-11-24 Kodak Ag Kassettenentlade- und beladegeraet
GB8712115D0 (en) 1987-05-22 1987-06-24 Hoffmann La Roche Pyrimidine derivatives
IL87646A (en) * 1987-09-03 1994-07-31 Sloan Kettering Inst Cancer Preparation for the treatment of hepatitis virus containing 1 -) 2 '- Deoxy - 2' - Fluoro - Beta - B - D - Arabino - Furanozil (- 5 - Orcil
US5246924A (en) 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
EP0380558A4 (en) 1987-09-22 1991-07-31 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
JPH01100190A (ja) * 1987-10-12 1989-04-18 Asahi Glass Co Ltd ヌクレオシド類
US4908440A (en) * 1987-11-12 1990-03-13 Bristol Myers Company 2',3'-dideoxy-2'-fluoroarabinopyrimidine nucleosides
SU1500645A1 (ru) * 1987-12-18 1989-08-15 Inst Bioorg Chimii 3'-фтор-з'-дезоксирибонуклеозиды, проявляющие цитостатическую активность
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
GB8813148D0 (en) * 1988-06-03 1988-07-06 Glaxo Group Ltd Chemical compounds
SE8802173D0 (sv) 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5034518A (en) 1989-05-23 1991-07-23 Southern Research Institute 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine nucleosides
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DD293498A5 (de) 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
EP0410660A1 (en) * 1989-07-24 1991-01-30 Glaxo Group Limited Cyclopentane derivatives
GB8920534D0 (en) * 1989-09-11 1989-10-25 Wellcome Found Antiviral compounds
US5886162A (en) 1989-11-03 1999-03-23 Research Foundation Of State University Of New York Lipophilic diakylaminomethylene prodrug derivatives for the inhibition of replication of viruses
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9007569D0 (en) * 1990-04-04 1990-05-30 Nycomed As Carbo-nucleoside derivatives
US5128458A (en) 1990-04-20 1992-07-07 Southern Research Institute 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
JPH05507279A (ja) 1990-05-29 1993-10-21 ネクススター・ファーマシューティカルズ・インコーポレイテッド グリセロールジ―およびトリホスフェート誘導体の合成
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
EP0463470A3 (en) 1990-06-22 1992-08-05 F. Hoffmann-La Roche Ag Process for the preparation of a fluorotetrahydrofuranone derivative
US5817799A (en) * 1990-07-23 1998-10-06 The United States Of America As Represented By The Department Of Health And Human Services 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
IT1246983B (it) 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
EP0626970A1 (en) 1992-12-18 1994-12-07 The University Of Alberta Dihydropyrimidine nucleosides with antiviral properties
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
US5458773A (en) * 1993-04-19 1995-10-17 Holland; Herbert W. Bilge oil absorber and solidifier
WO1994026273A1 (en) 1993-05-12 1994-11-24 Hostetler Karl Y Acyclovir derivatives for topical use
US5424416A (en) 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5446045A (en) * 1993-12-20 1995-08-29 Revankar; Ganapathi R. Antiviral guanine analogs
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5633367A (en) 1995-03-24 1997-05-27 Eli Lilly And Company Process for the preparation of a 2-substituted 3,3-difluorofuran
PT831852E (pt) * 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
GB9517022D0 (en) * 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
WO1997012033A1 (en) 1995-09-27 1997-04-03 Emory University Recombinant hepatitis c virus rna replicase
US5856085A (en) * 1995-12-01 1999-01-05 The Penn State Research Foundation Compositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity
GB9602025D0 (en) 1996-02-01 1996-04-03 Amersham Int Plc Nucleoside analogues
US5684143A (en) * 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
WO1997038001A1 (en) * 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES
CA2224165A1 (en) * 1996-04-09 1997-10-16 Yamasa Corporation 9-(2-deoxy-2-fluoro-4-thio-.beta.-d-arabinofuranosyl)purine derivatives
EP0929218A4 (en) 1996-10-30 2001-05-16 Univ North Carolina P2Y RECEPTOR ANTAGONISTS
WO1999043691A1 (en) * 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
WO2000026225A2 (en) * 1998-11-05 2000-05-11 Centre National De La Recherche Scientifique Nucleosides with anti-hepatitis b virus activity
US6407077B1 (en) * 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US6232058B1 (en) * 2000-01-11 2001-05-15 Eastman Kodak Company High-speed high quality direct radiographic film
US6348857B1 (en) * 2000-08-31 2002-02-19 Tzu-Lung Hsu Warning device for door lock of car

Also Published As

Publication number Publication date
DE69933860T2 (de) 2007-05-31
DE69933860D1 (de) 2006-12-14
IL200914A0 (en) 2010-05-17
KR20010082516A (ko) 2001-08-30
KR100954390B1 (ko) 2010-04-26
US20130157971A1 (en) 2013-06-20
IL138037A (en) 2010-05-17
US20040254141A1 (en) 2004-12-16
US8168583B2 (en) 2012-05-01
CN100349913C (zh) 2007-11-21
AU2787199A (en) 1999-09-15
JP2002504558A (ja) 2002-02-12
JP2010174019A (ja) 2010-08-12
EA200000870A1 (ru) 2001-08-27
KR20090009338A (ko) 2009-01-22
US7307065B2 (en) 2007-12-11
US6911424B2 (en) 2005-06-28
AU2003244569B2 (en) 2007-04-05
DK1058686T3 (da) 2007-03-05
CA2322008C (en) 2011-06-28
US9180138B2 (en) 2015-11-10
KR100719606B1 (ko) 2007-05-17
US7662938B2 (en) 2010-02-16
IL138037A0 (en) 2001-10-31
US9861652B2 (en) 2018-01-09
CA2322008A1 (en) 1999-09-02
KR20080032262A (ko) 2008-04-14
US6348587B1 (en) 2002-02-19
BR9908270A (pt) 2004-06-29
AU2003244569A1 (en) 2003-10-02
US20080300398A1 (en) 2008-12-04
ES2276515T3 (es) 2007-06-16
MXPA00008348A (es) 2005-07-15
PT1058686E (pt) 2007-01-31
EP1058686A1 (en) 2000-12-13
EP2392580A1 (en) 2011-12-07
KR100965488B1 (ko) 2010-06-24
CN1332747A (zh) 2002-01-23
US20160158266A1 (en) 2016-06-09
EP1058686B1 (en) 2006-11-02
EP2390257A1 (en) 2011-11-30
EA008609B1 (ru) 2007-06-29
ATE344271T1 (de) 2006-11-15
US20100173863A1 (en) 2010-07-08
US20020198171A1 (en) 2002-12-26
WO1999043691A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
DE69933860D1 (de) 2'-fluoronukleoside
ATE295849T1 (de) Aryl-ester phosphoramidatderivate von 2',3'- didehydronukleoside
PL409123A1 (pl) Związki, ich zastosowanie i kompozycje do leczenia wirusowego zapalenia wątroby typu C
CA2190983A1 (en) New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs
FI104176B (fi) Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi
LU91348I2 (fr) Telbivudine et ses sels pharmaceutiquement acceptables
CA2282585A1 (en) Pyrazine compounds
MY103801A (en) Dideoxydidehydrocarbocyclic nucleosides
KR910021246A (ko) 인지질 기제의 제약학적 조성물
KR910000730A (ko) N-헤테로아릴-푸린-6-아민, 이의 제조방법 및 약제로서의 이의 용도
KR900014388A (ko) 에세롤린의 카보네이트 유도체, 이의 제조방법 및 약제로서의 용도
ATE183394T1 (de) Verwendung von phosphorsäurediester-verbindungen zur unterdrückung von krebsmetastasen in der leber
BRPI9916820A2 (pt) Formulações farmacêuticas
EP1754710A3 (en) 2'-Fluoroncucleosides
DK561487A (da) 4-phenylsulfonyl-3,4-dihydro-2(1h)-quinoxalinon-1-alkansyre-forbindelser og farmaceutiske praeparater indeholdende disse
DE60003194D1 (de) Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren
ES528453A0 (es) Procedimiento de preparacion de nuevos derivados piridinicos y de sus sales de adicion acidas y cuaternarias
ES8205224A1 (es) Un procedimiento para la preparacion de acidos 1-carbadetiapen-2-em-3-carboxilios 6-1-y 2-sustituidos.
ATE41659T1 (de) Benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen.
DK216186A (da) Hexensyrer
GB2152508A (en) Pyrimidine derivatives
SE8705196D0 (sv) Pyrimidinderivat
CA2141030A1 (en) Liponucleotides of seco-nucleosides, their production as well as their use as antiviral pharmaceutical agents
CY1117836T1 (el) Βητα-l-2'-δεοξυ-νουκλεοσιδια για την θεραπεια ηπατιτιδας β
PT84160B (pt) Processo para a preparacao de derivados de 1-acilaminometil-imidazo {1,2-a} quinolainas e de composicoes farmaceuticas que os contem